chevron_leftBack
As of 24 April 2025, Bioqual, Inc. has a market cap of $49.19M USD, ranking #24841 globally and #3832 in the United States. It ranks #2520 in the Healthcare sector, and #125 in the Diagnostics & Research industry.
Key Stats
Market Cap
$49.19MUSD
Enterprise Value
$55.89MUSD
Revenue (TTM)
$49.0MUSD
EBITDA (TTM)
-$999.51KUSD
Net Income (TTM)
-$2.13MUSD
EBITDA Margin
-2%
Profit Margin
-4.3%
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mark Lewis
open_in_new
Employees
113
Founded
1981
Website
bioqual.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -4.4% | -1.8% | -8.3% | -15% | -19% | -31% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BIOQ
Bioqual Inc
ISIN: US09065J1016
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
55.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Bioqual, Inc.
Bioqual, Inc. provides in-vivo and in-vitro pre-clinical research services to commercial and government clients in the United States. The company provides research services in the areas of COVID-19, AIDS, influenza, RSV infection, and flavivirus infections, including zika, dengue, malaria, hepatitis, and cancer. Its services also include sample processing, virus stock generation, quantitation of infectious virus, virus neutralization assays, hemagglutination inhibition assay, quantitative PCR, antigen and antibody ELISA detection assays, flow cytometry, lymphocyte proliferation, and other cell-based assays. In addition, the company provides animal research model related services. Bioqual, Inc. was founded in 1981 and is based in Rockville, Maryland.
